[171 Pages Report] The overall peptide synthesis market was valued at USD 292.4 million in 2017 and is projected to reach USD 426.4 million by 2023, at a CAGR of 6.5% during the forecast period. Market growth can be attributed to increasing use of peptides in pharmaceutical drugs, increase in research activities and availability of funding for R&D, and the development of advanced peptide synthesizers. The base year considered for the study is 2017, and the forecast has been provided for the period between 2018 and 2023.

Market Dynamics

Drivers

Increasing use of peptides in pharmaceutical drugs

Increase in research activities and availability of funding for R&D

Development of advanced peptide synthesizers

Restraints

Lack of a unified set of regulations for therapeutic peptides

Opportunities

Emerging markets in the Asia Pacific region

Challenges

Issues associated with the route of administration of peptide drugs

Increasing use of peptides in pharmaceutical drugs drives the global peptide synthesis market

Peptides are highly active and highly specific drug substances. Due to the diversity of their biological functions, they are used in an extensive range of therapeutic areas. Also, they are increasingly entering drug development pathways as potential active pharmaceutical ingredients due to their large chemical space, high biological activity, high specificity, relative ease of synthesis, ready availability, and low toxicity.

Oncology, diabetes, and obesity are three prominent therapeutic areas in which peptides generate billions of dollars in revenues. As a drug modality, peptides and peptidomimetics occupy the interface between small molecules and larger biological drugs with the potential to have the specificity of antibodies and the bioavailability of small molecules. Moreover, peptides provide researchers with viable options for discovery, optimization, and manufacture, as they can be synthesized chemically or expressed by recombinant systems. As a result of these advantages, pharmaceutical companies are increasingly focusing on the development of peptide-based drugs.

The following are the major objectives of the study.

To define, describe, and forecast the peptide synthesis market on the basis of product, technology, end user, and region

During this research study, major players operating in the peptide synthesis market in various regions have been identified, and their offerings, regional presence, and distribution channels have been analyzed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Factiva, along with primary respondents. The entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) pertaining to the market. The figure below shows the breakdown of the primaries on the basis of the company type, designation, and region considered during the research study.

Major Market Developments

In 2017, Merck acquired Grzybowski Scientific Inventions (GSI) (US). This acquisition helped the company to expand its chemical synthesis portfolio.

In 2015, Merck acquired Sigma-Aldrich Corporation (US). This acquisition strengthened Mercks Life Science segment. Sigma-Aldrichs SAFC Commercial business is now a part of Mercks Life Science segment

Target Audience:

Biotechnology & pharmaceutical companies

Market research and consulting firms

Venture capitalists and investors

Research & development companies

Contract research organizations (CROs)

Academic research institutes

Government institutes

Report Scope

Peptide Synthesis Market, By Product

Reagents

Equipment

Peptide Synthesizers

Chromatography equipment

Lyophilizers

Peptide Synthesis Market, By Technology

Solid-phase Peptide Synthesis

Liquid-phase Peptide Synthesis

Hybrid & Recombinant Technology

Peptide Synthesis Market, By End User

Pharmaceutical and Biotechnology Companies

Contract Development and Manufacturing Organizations

Academic and Research Institutes

Peptide Synthesis Market, By Region

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Rest of Asia Pacific

Latin America

Middle East and Africa

Critical questions which the report answers

What are new application areas which the peptide synthesis companies are exploring?

Which are the key players in the market and how intense is the competition?

Available customizations

Based on the given market data, MarketsandMarkets offers customizations in the reports as per the clients specific requirements. The available customization options are as follows:

Geographic Analysis

Further breakdown of the Rest of Asia Pacific market into South Korea, Australia, New Zealand, and others

Further breakdown of the Rest of Europe (RoE) market into Belgium, Russia, the Netherlands, Switzerland, and others

Further breakdown of the Rest of Latin America(RoLATAM) market into Argentina, Colombia, Chile, and others

Company Information

Detailed analysis and profiling of additional market players

The overall peptide synthesis market is projected to reach USD 426.4 million by 2023 from USD 310.5 million in 2018, at a CAGR of 6.5% during the forecast period. Factors such as the growing use of peptides in pharmaceutical drugs, increase in research activities and availability of funding for R&D, and the development of advanced peptide synthesizers are expected to drive the growth of the market.

Peptides are organic molecules consisting of amino acids linked by a peptide (amide) bond. Peptide synthesis is the process of making short sequences of peptides by the condensation reaction of the carboxyl group of one amino acid to the amino group of another.

The peptide synthesis market has been segmented, on the bassis of product, into reagents and equipment. The market for equipment segment is expected to grow at the highest CAGR between 2018 and 2023. On the other hand, among all the equipment, peptide synthesizers are most widely used for peptide synthesis process. The high adoption of these instruments is contributing to the rapid growth of the market.

The peptide synthesis market in APAC is expected to grow at the highest CAGR during the forecast period. With significant growth in the research industry in the past few years, China and India have emerged as high-growth markets peptide synthesis. The research industry in this region has grown significantly over the years; manufacturers are now focusing on providing well-established technologies to ensure sustainable and strong revenue growth from this region. Biotechnology-based drugs are anticipated to be one of the key drivers for the research industry, as reflected in the increase in research being undertaken and government funds provided for these drugs. Thus, the increasing demand for novel antibody and protein-based drugs along with growing investments by the public and private sectors in life science research are expected to drive the APAC market in the coming years.

Solid-Phase Synthesis

Solid-phase synthesis is the synthesis of chemical compounds whereby the reactant molecule is chemically bound to an insoluble material. It is a step-wise, cyclic procedure to ensure proper incorporation of amino acids (AAs) into the growing peptide chain. This method involves the use of a resin, which is a non-soluble, polymer-based material. The large share of this segment can primarily be attributed to the wide range of advantages associated with the use of solid-phase synthesis, such as ease of operation, easy purification, short production cycles, high-level automation, and synthesis capabilities of long peptides in small quantities of amino acids.

Solution-Phase Synthesis

Solution-phase synthesis, or liquid-phase synthesis, is the traditional method of peptide production. It has, however, been replaced in most labs by solid-phase synthesis. SPS is based on the coupling of single amino acids in solutions. SPS is used in the large-scale production of peptides for industrial purposes. The prime advantage of this method is that the intermediate products can be deprotected and purified. Factors such as large quantities of high-quality peptides, easy and inexpensive scale-up, and the procedure being suitable for ligation technologies are supporting the growth of the solution-phase synthesis market.

Hybrid and Recombinant Technology

In hybrid technology, solid and liquid phase synthesis methodologies are used together to synthesize peptides. This approach uses solid phase method on resins, and then the amino acid segments are condensed in solution to construct the full peptide sequence. Factors such as the ability to synthesize peptides with higher complexity or length and biologically active conformation or higher immunogenicity as compared to chemical synthesis are further expected to increase the demand for hybrid and recombinant technologies in the next few years.

Critical questions the report answers:

Where will all these developments take the industry in the mid to long term?

What are the major end users and technologies of peptide synthesis?

Lack of unified set of regulations for therapeutic peptides is a major factor restraining the growth of the market. The development of a unified set of regulatory guidelines that can effectively address the safety and quality requirements for a diverse group of molecular entities with various unique mechanisms of action is a challenging task. There are no formal guidelines from any regulatory agency for the development of this class of therapeutics. This lack of a unified set of regulations has made it difficult to secure approvals for therapeutic peptides, which in turn is limiting their application areas. This is considered as a major factor restraining the growth of the global peptide synthesis market.